BriaCell Therapeutics Corp. (BCTX) |
|
5.4401 -0.07 (-1.27%)
|
09-26 14:36 |
|
Open: |
5.6 |
Pre. Close: |
5.51 |
|
High:
|
5.69 |
Low:
|
5.4201 |
|
Volume:
|
24,150 |
Market Cap:
|
87(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 2:17:15 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 7.87 One year: 8.86 |
| Support: |
Support1: 5.36 Support2: 4.46 |
| Resistance: |
Resistance1: 6.74 Resistance2: 7.59 |
| Pivot: |
6.04  |
| Moving Average: |
MA(5): 5.62 MA(20): 6.28
MA(100): 6.43 MA(250): 6.41 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 7.4 %D(3): 7.3 |
| RSI: |
RSI(14): 31.2 |
| 52-week: |
High: 8.1 Low: 4.23 |
| Average Vol(K): |
3-Month: 87 (K) 10-Days: 76 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BCTX ] has closed above bottom band by 20.3%. Bollinger Bands are 51% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.52 - 5.55 |
5.55 - 5.58 |
|
Low:
|
5.31 - 5.35 |
5.35 - 5.39 |
|
Close:
|
5.45 - 5.51 |
5.51 - 5.56 |
|
Company Description |
|
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada. |
Headline News |
Tue, 26 Sep 2023
Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference - Investing News Network
Tue, 26 Sep 2023
Should You Buy Briacell Therapeutics Corp (BCTX) in Biotechnology Industry? - InvestorsObserver
Wed, 20 Sep 2023
AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS - Investing News Network
Wed, 13 Sep 2023
Wave of FDA Fast Track Designations Highlight Biotech Momentum ... - PR Newswire
Fri, 08 Sep 2023
BriaCell Reports Benchmark-Beating Patient Survival and Clinical ... - BioSpace
Thu, 31 Aug 2023
AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE - Investing News Network
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
16 (M) |
| Shares Float |
12 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
1,130 (K) |
|
Shares Short P.Month
|
1,050 (K) |
Stock Financials |
|
EPS
|
-0.19 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-0.38 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-34.2 |
|
Return on Equity (ttm)
|
-91.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.31 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-16 (M) |
|
Levered Free Cash Flow
|
-9 (M) |
Stock Valuations |
|
PE Ratio
|
-29.42 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-14.71 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-5.53 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
